	US 12,312,607 B2
	AAV9 affinity agents
William Scott Dodson, Lebanon, NH (US); Brandon Kier, Lebanon, NH (US); Brandon Coyle, Lebanon, NH (US); Sarah Valentini, Lebanon, NH (US); Thomas Scanlon, Lebanon, NH (US); and Warren Kett, Lebanon, NH (US)
Assigned to Avitide LLC, Lebanon, NH (US)
Appl. No. 17/613,427
Filed by Avitide LLC, Lebanon, NH (US)
PCT Filed May 22, 2020, PCT No. PCT/US2020/034340 § 371(c)(1), (2) Date Nov. 22, 2021, PCT Pub. No. WO2020/242988, PCT Pub. Date Dec. 3, 2020.
Claims priority of provisional application 62/949,878, filed on Dec. 18, 2019.
Claims priority of provisional application 62/852,717, filed on May 24, 2019.
Prior Publication US 2022/0213447 A1, Jul. 7, 2022
Int. Cl. C12N 7/00 (2006.01); B01D 15/32 (2006.01); B01D 15/38 (2006.01); C07K 7/02 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01)

CPC C12N 7/00 (2013.01) [B01D 15/325 (2013.01); B01D 15/3828 (2013.01); C07K 7/02 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C12N 2750/14151 (2013.01)]

18 Claims

1. An affinity agent comprising a ligand, wherein the ligand comprises a binding motif selected from the group consisting of:

(a) SEQ ID NOs: 1-5; and

(b) an amino acid sequence that differs from SEQ ID NOs: 1-5 by no more than two substitutions, additions, or deletions.